📰 Crypto Market Hotspot News Digest
1. Mecox Pharma-B advances clinical progress for a new drug targeting acute ischemic stroke
Mecox Pharma-B disclosed that its candidate drug MT1002 for acute ischemic stroke has completed the first-patient enrollment in its Phase Ib/II clinical trials, and the project has entered a phase of substantive advancement. According to the materials, MT1002 is a dual-target antagonist of coagulation factor II and GPIIb/IIIa, combining anticoagulant and antiplatelet mechanisms. This multicenter study will first evaluate safety and pharmacokinetics, and then compare with standard treatment in a larger patient cohort to observe overall therapeutic efficacy and future application prospects. For the market, R&D progress on such innovative drugs can help increase attention to relevant healthcare sectors, but clinical outcomes still need ongoing monitoring.
2. Polymarket World Cup goal market sees sizable “smart money” positioning
Market monitoring of prediction shows that, in Polymarket’s event regarding the Brazil vs. Norway match, an address with a relatively high cumulative profit has bought a position of roughly $200,000 in “regular time total goals greater than 2.5” at an average entry price of about 54.5 cents, and the position is already showing some unrealized gains. This trend reflects that capital in prediction markets is increasingly engaging in high-frequency pricing and trading games around sports event outcomes. It also indicates that on-chain “smart money” behavior remains a key indicator for short-term traders to watch. Considering the teams’ recent performances, the pressure of knockout-stage competition, and the uncertainty of the match, the heat of relevant contracts is expected to remain elevated. However, users should be mindful of risks and avoid blindly following.
#Polymarket #链上热点 #预测市场
1. Mecox Pharma-B advances clinical progress for a new drug targeting acute ischemic stroke
Mecox Pharma-B disclosed that its candidate drug MT1002 for acute ischemic stroke has completed the first-patient enrollment in its Phase Ib/II clinical trials, and the project has entered a phase of substantive advancement. According to the materials, MT1002 is a dual-target antagonist of coagulation factor II and GPIIb/IIIa, combining anticoagulant and antiplatelet mechanisms. This multicenter study will first evaluate safety and pharmacokinetics, and then compare with standard treatment in a larger patient cohort to observe overall therapeutic efficacy and future application prospects. For the market, R&D progress on such innovative drugs can help increase attention to relevant healthcare sectors, but clinical outcomes still need ongoing monitoring.
2. Polymarket World Cup goal market sees sizable “smart money” positioning
Market monitoring of prediction shows that, in Polymarket’s event regarding the Brazil vs. Norway match, an address with a relatively high cumulative profit has bought a position of roughly $200,000 in “regular time total goals greater than 2.5” at an average entry price of about 54.5 cents, and the position is already showing some unrealized gains. This trend reflects that capital in prediction markets is increasingly engaging in high-frequency pricing and trading games around sports event outcomes. It also indicates that on-chain “smart money” behavior remains a key indicator for short-term traders to watch. Considering the teams’ recent performances, the pressure of knockout-stage competition, and the uncertainty of the match, the heat of relevant contracts is expected to remain elevated. However, users should be mindful of risks and avoid blindly following.
#Polymarket #链上热点 #预测市场